Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies

• Published in: European journal of clinical microbiology & infectious diseases Vol. 39; no. 4; pp. 613 - 627
• Main Authors: Ebrahimzadeh Leylabadlo, Hamed, Ghotaslou, Reza, Samadi Kafil, Hossein, Feizabadi, Mohammad Mehdi, Moaddab, Seyed Yaghoub, Farajnia, Safar, Sheykhsaran, Elham, Sanaie, Sarvin, Shanehbandi, Dariush, Bannazadeh Baghi, Hossein
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.04.2020; Springer Nature B.V
• Subjects: Biomedical and Life Sciences; Biomedicine; Environmental factors; Fatty liver; Fecal microflora; Hepatocytes; Inflammation; Internal Medicine; Intestinal microflora; Lipids; Literature reviews; Liver; Liver diseases; Medical Microbiology; Microbiota; Microorganisms; Probiotics; Review; Search engines; Steatosis; Transplantation; Probiotics; Microbiota; Non-alcoholic fatty liver disease; Microbiome; Prebiotics
• ISSN: 0934-9723; 1435-4373
• DOI: 10.1007/s10096-019-03746-1

Non-alcoholic fatty liver disease (NAFLD) is the well-known disease of the liver in adults and children throughout the world. The main manifestations related to NAFLD are an unusual storage of lipid in hepatocytes (hepatic steatosis) and progression of inflammation for non-alcoholic steatohepatitis (NASH). NAFLD is described as a multifactorial complication due to the genetic predisposition, metabolic functions, inflammatory, gut microbiota (GM), and environmental factors. The GM dysregulation among these factors is correlated to NAFLD development. In recent decades, advanced microbial profiling methods are continuing to shed light on the nature of the changes in the GM caused by NASH and NAFLD. In the current review, we aim to perform a literature review in different library databases and electronic searches (Science Direct, PubMed, and Google Scholar) which were randomly obtained. This will be done in order to provide an overview of the relation between GM and NAFLD, and the role of prebiotics, probiotics, and fecal microbiota transplantation (FMT), as potential therapeutic challenges for NAFLD.